Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Summit licenses imino sugar compound for infectious diseases

This article was originally published in Scrip

Executive Summary

Summit has licensed the worldwide rights to a sugar compound with potential for treating infectious diseases associated with bio-terrorism to Evolva Biotech. The UK company will receive an undisclosed payment for the second-generation imino sugar SMT 14400. Summit is also eligible for payment on filing an IND, which is expected in 2010, and further development and regulatory milestones. It will receive tiered royalties of up to a low-teen percentage and sales-related milestones on successful commercialisation. Evolva will cover all developmental costs for the initial synthesis work. The agreement replaces a co-development agreement signed in July 2007. SMT 14400 is an immunomodulator that selectively boosts aspects of the human immune system. In vivo studies have shown it to be active against viral and bacterial pathogens and well tolerated. SMT 14400 is the first compound that Summit has licensed from its proprietary collection of second-generation compounds.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts